Bolt Biotherapeutics, Inc. financial data

Symbol
BOLT on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 Chesapeake Drive, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Bolt Therapeutics, Inc. (to 5/7/2015)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 457 % -38.2%
Debt-to-equity 43.1 % +28.8%
Return On Equity -69.5 % -46%
Return On Assets -48.6 % -36.2%
Operating Margin -776 % +27.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.3M shares +0.81%
Common Stock, Shares, Outstanding 38.3M shares +0.81%
Entity Public Float 32.1M USD -37.5%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 38.3M shares +1.01%
Weighted Average Number of Shares Outstanding, Diluted 38.3M shares +1.01%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.78M USD +35.9%
Research and Development Expense 62.1M USD +0.01%
General and Administrative Expense 20M USD -11.3%
Operating Income (Loss) -75.9M USD +2.03%
Nonoperating Income (Expense) 10.8M USD +75%
Net Income (Loss) Attributable to Parent -65.1M USD +8.71%
Earnings Per Share, Basic -1.71 USD/shares +9.52%
Earnings Per Share, Diluted -1.71 USD/shares +9.52%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.37M USD +2.25%
Cash, Cash Equivalents, and Short-term Investments 84.4M USD -40.3%
Assets, Current 57.1M USD -54.5%
Property, Plant and Equipment, Net 3.57M USD -32.3%
Operating Lease, Right-of-Use Asset 16.8M USD -15.7%
Other Assets, Noncurrent 287K USD -78.6%
Assets 109M USD -37.7%
Accounts Payable, Current 1.48M USD -59.8%
Employee-related Liabilities, Current 3.25M USD -33.5%
Contract with Customer, Liability, Current 1.4M USD
Liabilities, Current 18.1M USD -3.56%
Operating Lease, Liability, Noncurrent 15.4M USD -15.5%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 37.3M USD -20.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 205K USD
Retained Earnings (Accumulated Deficit) -411M USD -18.8%
Stockholders' Equity Attributable to Parent 72M USD -43.8%
Liabilities and Equity 109M USD -37.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.8M USD +28.4%
Net Cash Provided by (Used in) Financing Activities 107K USD
Net Cash Provided by (Used in) Investing Activities 10.2M USD -64.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 38.3M shares +0.81%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.55M USD -217%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 11.1M USD +1.96%
Deferred Tax Assets, Valuation Allowance 83.7M USD +22.7%
Deferred Tax Assets, Gross 89.7M USD +19.2%
Operating Lease, Liability 18.2M USD -12.8%
Depreciation 1.9M USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.7M USD +7.24%
Lessee, Operating Lease, Liability, to be Paid 25.9M USD -15.8%
Property, Plant and Equipment, Gross 10.4M USD -1.33%
Operating Lease, Liability, Current 2.82M USD +5.37%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.48M USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.34M USD -11.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.73M USD -21.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.6M USD +3.39%
Deferred Tax Assets, Operating Loss Carryforwards 47.3M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 18.7M USD +35.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.72M USD +3.39%
Operating Lease, Payments 1.2M USD +3.36%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 458K USD -1.93%
Deferred Tax Assets, Net of Valuation Allowance 5.98M USD -15.2%
Share-based Payment Arrangement, Expense 8.29M USD -10.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%